thymine has been researched along with DDPAC in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " fluoropyrimidine and irinotecan plus bevacizumab (control) as second-line treatment for metastatic colorectal cancer (mCRC)." | 9.69 | Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. ( Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T, 2023) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 8.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients." | 8.12 | Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). ( Dijksterhuis, WPM; Elferink, MAG; Hamers, PAH; Koopman, M; May, AM; Punt, CJA; Stellato, RK; Vink, GR, 2022) |
| " fluoropyrimidine and irinotecan plus bevacizumab (control) as second-line treatment for metastatic colorectal cancer (mCRC)." | 5.69 | Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. ( Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T, 2023) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 4.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients." | 4.12 | Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). ( Dijksterhuis, WPM; Elferink, MAG; Hamers, PAH; Koopman, M; May, AM; Punt, CJA; Stellato, RK; Vink, GR, 2022) |
| " We treated a co-culture comprised of human colorectal cancer (CRC) cells and peripheral blood mononuclear cells (PBMCs) with the nucleoside analogue trifluridine (FTD) and used scRNA-seq to analyze posttreatment gene expression profiles in thousands of individual cancer and immune cells concurrently." | 4.12 | Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model. ( Andersson, CR; Fasterius, E; Fryknäs, M; Jarvius, M; Larsson, R; Selvin, T, 2022) |
| " Among FTD/TPI-treated patients, frequencies of any-cause grade ≥ 3 adverse events (AEs) were similar across age subgroups (80% each), although grade ≥ 3 neutropenia was more frequent in older patients [40% (≥ 65 and ≥ 75 years); 29% (< 65 years)]; AE-related discontinuation rates did not increase with age [14% (< 65 years), 12% (≥ 65 years), and 12% (≥ 75 years)]." | 3.11 | Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). ( Alsina, M; Benhadji, KA; Cicin, I; Doi, T; Hosaka, H; Ilson, DH; Longo, F; Makris, L; Özgüroğlu, M; Ozyilkan, O; Park, D; Pericay, C; Santoro, A; Shitara, K; Thuss-Patience, P; Zaanan, A, 2022) |
| "Two families with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) resulting from the microtubule associated protein tau (MAPT) gene IVS10+16C>T splice site mutation are reported, members of which showed variable clinical phenotypes at presentation." | 1.35 | Intrafamilial clinical phenotypic heterogeneity with MAPT gene splice site IVS10+16C>T mutation. ( Larner, AJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (88.89) | 2.80 |
| Authors | Studies |
|---|---|
| Shitara, K | 4 |
| Doi, T | 4 |
| Hosaka, H | 1 |
| Thuss-Patience, P | 1 |
| Santoro, A | 1 |
| Longo, F | 1 |
| Ozyilkan, O | 1 |
| Cicin, I | 1 |
| Park, D | 1 |
| Zaanan, A | 1 |
| Pericay, C | 1 |
| Özgüroğlu, M | 1 |
| Alsina, M | 1 |
| Makris, L | 4 |
| Benhadji, KA | 4 |
| Ilson, DH | 4 |
| Coutzac, C | 1 |
| Trouilloud, I | 1 |
| Artru, P | 1 |
| Henriques, J | 1 |
| Masson, T | 1 |
| Doat, S | 1 |
| Bouché, O | 1 |
| Coriat, R | 1 |
| Saint, A | 1 |
| Moulin, V | 1 |
| Vernerey, D | 1 |
| Gallois, C | 1 |
| De La Fouchardière, C | 1 |
| Tougeron, D | 1 |
| Taieb, J | 1 |
| Hamers, PAH | 1 |
| Vink, GR | 1 |
| Elferink, MAG | 1 |
| Stellato, RK | 1 |
| Dijksterhuis, WPM | 1 |
| Punt, CJA | 1 |
| Koopman, M | 1 |
| May, AM | 1 |
| Yoshino, T | 5 |
| Van Cutsem, E | 4 |
| Li, J | 1 |
| Shen, L | 1 |
| Kim, TW | 1 |
| Sriuranpong, V | 1 |
| Xuereb, L | 1 |
| Aubel, P | 1 |
| Fougeray, R | 1 |
| Cattan, V | 1 |
| Amellal, N | 1 |
| Ohtsu, A | 4 |
| Mayer, RJ | 1 |
| Selvin, T | 1 |
| Fasterius, E | 1 |
| Jarvius, M | 1 |
| Fryknäs, M | 1 |
| Larsson, R | 1 |
| Andersson, CR | 1 |
| Hochster, H | 3 |
| Mayer, R | 3 |
| Falcone, A | 3 |
| Arkenau, HT | 3 |
| George, B | 3 |
| Tabernero, J | 3 |
| Kuboki, Y | 1 |
| Terazawa, T | 1 |
| Masuishi, T | 2 |
| Nakamura, M | 1 |
| Watanabe, J | 1 |
| Ojima, H | 1 |
| Makiyama, A | 2 |
| Kotaka, M | 1 |
| Hara, H | 1 |
| Kagawa, Y | 1 |
| Sugimoto, N | 1 |
| Kawakami, H | 1 |
| Takashima, A | 2 |
| Kajiwara, T | 2 |
| Oki, E | 1 |
| Sunakawa, Y | 1 |
| Ishihara, S | 1 |
| Taniguchi, H | 1 |
| Nakajima, TE | 1 |
| Morita, S | 1 |
| Shirao, K | 1 |
| Takenaka, N | 1 |
| Ozawa, D | 1 |
| Shiroyama, M | 1 |
| Fukuoka, S | 1 |
| Kumekawa, Y | 1 |
| Yamazaki, K | 1 |
| Shimada, Y | 1 |
| Esaki, T | 1 |
| Moriwaki, T | 1 |
| Larner, AJ | 1 |
1 review available for thymine and DDPAC
| Article | Year |
|---|---|
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Topics: Codon; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Mutation; Proto-Onc | 2022 |
3 trials available for thymine and DDPAC
5 other studies available for thymine and DDPAC
| Article | Year |
|---|---|
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model.
Topics: Colorectal Neoplasms; Frontotemporal Dementia; Humans; Leukocytes, Mononuclear; Pyrrolidines; Single | 2022 |
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Intrafamilial clinical phenotypic heterogeneity with MAPT gene splice site IVS10+16C>T mutation.
Topics: Atrophy; Base Sequence; Brain; Brain Chemistry; Cytosine; Disease Progression; DNA; DNA Mutational A | 2009 |